We Work With

A critical factor for NEUROFIX's success both as a company and as a generator of actionable knowledge in the area of neurological therapies is our networking with other players in the national biotech sector, with whom we regularly cooperate in research projects and exchange knowledge, expertise and professional influence (Figure 3). We intend to rely on this infrastructure to improve our performance in specific tasks of THERASPINE via subcontracting agreements

Basic Research

• Universidad de Salamanca

National Hospital for Paraplegics

• University of Leon

• University of Balearic Islands

Clinical Development

• Qualitrials

Chemical Synthesis

• Medalchemy

• Labsan/Tecnalia

IP Management

• MIA Patents

• Sterne-Kessler-Goldstein-Fox

Regulatory Advisory

QualitecFarma

• BEGA

At the moment we are participating in several projects within network, including:

University of the Balearic Islands-UIB (Spain)

NEUROFIX has a contract with this institution (starting date 01/01/2017) to develop liposomederivatized formulations for NFX81 and to investigate its mechanism of action. The understanding of this mechanism is critical to the approval process and also to design new and better future therapies.

University of Salamanca (Spain)

We are currently negotiating with a GLP-certified group to perform pharmacokinetic studies. They will undertake the measurement of NFX81 levels in CSF, required to complete its preclinical phase (in synergy of WP4 of THERASPINE).

logoulen

University of Leon (Spain)

We are cooperating with this university and biotech companies to elucidate the mode of action of NFX204, a new development of our company designed to treat stroke. This molecule is still at an early stage of our R&D pipeline.

National Hospital for Paraplegics of Toledo (Spain)

NEUROFIX has a contract (starting 01/01/2017) with this center to investigate the efficacy of different NFX81 formulations (in line with WP4 of this proposal). We will test the efficacy of NFX81 with liposomes instead of albumin for clinical trials in humans. Albumin is a very efficient vehicle for the active principle in NFX81 in animal models, making its release more progressive and durable.

However, using a human protein in the formulation may cause approval delays. Liposomes are a wellestablished vehicle for long-term delivery of APIs and raises less concerns and regulatory burden.